- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S7563
| Related Targets | PI3K mTOR GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A PDK |
|---|---|
| Other Akt Products | MK-2206 Dihydrochloride SC79 AZD5363 (Capivasertib) Ipatasertib (GDC-0068) Perifosine GSK690693 Triciribine (API-2) CCT128930 Afuresertib (GSK2110183) A-674563 HCl |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| insect cells | Function assay | 50 mins | Inhibition of N-terminal His-tagged full-length human recombinant p70S6K expressed in Spodoptera frugiperda insect cells using AKRRRLSSLRA substrate and and [gamma-33P-ATP] incubated for 50 mins by scintillation counting method, IC50=0.012μM. | ChEMBL | ||
| U87MG | Function assay | 1 hr | Inhibition of PKB in human U87MG cells assessed as reduction in Gsk3beta Ser9 phosphorylation incubated for 1 hr by time-resolved fluorescence based assay, IC50=1.1μM. | ChEMBL | ||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 62 mg/mL
(197.59 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 313.78 | Formula | C17H16ClN3O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1056901-62-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC(=CC=C1C2=CNN=C2)C(CN)(C3=CC=C(C=C3)Cl)O | ||
| Targets/IC50/Ki |
PKA
(Cell-free assay) 3 nM
ROCK2
(Cell-free assay) 4 nM
ROCK1
(Cell-free assay) 6 nM
p70S6K
(Cell-free assay) 8 nM
Akt1
(Cell-free assay) 38 nM
Akt3
(Cell-free assay) 50 nM
SGK3
(Cell-free assay) 63 nM
RSK1
(Cell-free assay) 85 nM
Akt2
(Cell-free assay) 402 nM
|
|---|---|
| In vitro |
AT13148, as a multi-AGC kinase inhibitor, potently inhibits proliferation with GI50 values of 1.5 to 3.8 μM across a selected panel of cancer cell lines with deregulation of PI3K-AKT-mTOR or RAS-RAF pathways. In PTEN-deficient MES-SA cells, this compound also inhibits AKT and p70S6K signaling.
|
| Kinase Assay |
In vitro kinase assays
|
|
AT13148 is assayed against 40 kinases and the percentage inhibition at 10 μM of this compound is determined. Individual IC50 values are measured for selected kinases using ATP concentrations equivalent to the Km for each enzyme.
|
|
| In vivo |
AT13148 (50 mg/kg p.o.) markedly inhibits the activity of both AKT and p70S6K AGC kinases, and subsequently exhibits marked antitumor effects in human tumor xenografts.
|
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01585701 | Completed | Advanced Solid Tumours |
Cancer Research UK |
May 2012 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.